BioCentury-BayHelix East-West Biopharma Summit

For three decades, BioCentury has helped biotech executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem. The BioCentury-BayHelix East-West Biopharma Summit is a pan-Asia event gathering VCs, CEOs, chief financial officers (CFOs), chief business officers (CBOs) and decision-makers from Asia and the West who are shaping the future of biopharma innovation.

Cooley is proud to sponsor this year’s conference and speak on two panels in this year’s program.

For more information, please email Ann-Marie Eu.

Featured agenda items

Tuesday, 4 March 2025 | 10:00 – 10:45 am SGT

Capital Markets Showcase: Survival Tips

Biotechs in the East and West have to surmount the exhaustion of the prolonged bear market and present differentiated programs to attract investors. But the different regions have different challenges, meaning biotech executives have to understand their ecosystems and adapt in a fast-changing environment. Investors from global firms debated their tips on how biotechs can rise above the noise and attract critical cash infusions.

Session chair:

• Jeff Cranmer – Executive editor and head of daily global intelligence at BioCentury

Panelists:

• Luc Dochez – Managing partner at Droia Ventures
• Eugene Hong, MD – Managing director and head of pharmaceuticals and healthcare at DBS Bank
• Fong Ming Koh, PhD – Investment principal at LYFE Capital
• Andrew Lam, PharmD – Managing director and head of biotech at Ally Bridge
• Yiming Liu – Shanghai partner in charge at Cooley
• Jolene Ooi, PhD – Partner of investments at EDBI

Tuesday, 4 March 2025 | 4:00 – 4:45 pm

Dealmakers’ Showcase: Is Licensing Innovation from Asia Here to Stay?

The NewCo model and an early wave of M&A have injected energy into Asian biopharma executives and investors, who see a way to escape the region’s grueling bear markets and put their innovations in good hands in the US and Europe. This panel of pathfinding dealmakers discussed how they navigated this new landscape, providing insights on how Asian assets are valued and the trade-offs that must be made not only to find a deal but also to ensure that their assets reach their global promise.

Session chair:

• Lila Hope, PhD – Partner at Cooley

Panelists:

• Ming Fang – Senior director of search and evaluation at GSK
• Sridhar Gopal – Head of international business development at AbbVie
• Mia Hu – Investment director at Boehringer Ingelheim Venture Fund
• Ya-Ting Lei, PhD – Director of business development and licensing at Merck Group
• Makoto Sugita, PhD – President and chief marketing officer at Nxera Pharma Japan
• Qiusong Tang, PhD – Head of Roche Accelerator China